I’ve got a theory on why the phase 2 trials of the DEP drugs are never ending. Apologies if someone has already said this. SPL could end any of the trials today but then they would have only a short window (say 6 months) to license the drug. If not licensed in that time the drug would be moved to the discount rack and be worth virtually nothing. So they keep all three in the market, bubbling along in phase 2, hoping some combination with another drug will produce fabulous results and that a buyer will turn up.
Pretty clearly Sanofi have rejected DEP Docetaxel. It’s just been too long in phase. 2.
DEP Irinotecan was the great white hope two years ago when always mentioned first in company reports. Since then unfortunately, it seems trial results have not been impressive enough for Pfizer (who own Camptostar). It is now only mentioned after DEP Cabazitaxel. Perhaps Sanofi (owner of Jevtana) were showing some interest in the latter drug. But then why hasn’t a deal been done?
Maybe JF should change tack and move to a phase 3 trial for the best performing of the three drugs. There’s $54 million in the bank and the trial wouldn’t have to be huge as the underlying drug is already approved. Better than going broke slowly.
After 6 years I’ve lost confidence in SPL and I’ve changed my sentiment to sell. I’m going to wait for some good news so I’m not selling at the bottom and then get out.
Add to My Watchlist
What is My Watchlist?
